Abstract 790P
Background
HER2 is a transmembrane tyrosine kinase receptor, mediating cell proliferation and apoptosis inhibition. In breast and gastric tumors, HER2 -overexpression (HER2-OE) assessed by immunohistochemistry (IHC) is a validated prognostic and predictive biomarker with well-established scoring guidelines. However, its significance in GTs remains unclear, lacking no specific guidelines.
Methods
To establish prevalence of HER2-OE in GTs, archival formalin-fixed, paraffin-embedded tumor blocks from patients diagnosed at our academic institution were analyzed during 2023-2024. Tumor samples were stained using a validated HER2 monoplex-IHC panel (anti-HER2/neu 4B5 Rabbit monoclonal antibody) using Ventana system. HER2-OE was firstly scored using Breast Cancer ASCO-CAP (BCG) and subsequently ASCO-CAP-ASCP Gastroesophageal Adenocarcinoma (GEG) Guidelines. Concordance rates (CR) between both methods were calculated. HER2-OE scores were correlated with tumor molecular profiles.
Results
A total of 324 GTs were evaluated including 194 epithelial ovarian (OC), 80 endometrial (EC) and 31 cervical cancers (CC). Percentage of HER2-OE scores by BGC: 0, +1, +2, and +3 were 58%, 29%, 11% and 2%, respectively in all GTs. In OC: 56%, 30%, 12% and 2%. In EC: 51%, 34%, 13% and 2%. And, in CC: 65%, 19%, 9.7% and 6.3%. Percentage of HER2-OE scores by GEG: 0, +1, +2, +3 were 56%, 28%, 14% and 2%, respectively in all GTs. In OC: 55%, 29%, 14%, and 2%. In EC: 51%, 30%, 15% and 4%. And in CC, 55%, 26%, 13%, and 6%. Overall CR between BCG and GEG was 89.78%. CR in OC, EC an CC was: 92.78%, 85% and 80.65%, respectively. HER2-OE according to tumor molecular features are shown in the table. Table: 790P
| BCG | GEG | |||||||
| 0 | 1+ | 2+ | 3+ | 0 | 1+ | 2+ | 3+ | |
| OC HRD status N (%) | ||||||||
| HRD positive | 28 (61) | 13 (28) | 5(11) | 0 (0) | 27 (59) | 11 (24) | 8 (17) | 0 (0) |
| HRD negative | 17 (45) | 15 (39) | 5(13) | 1 (3) | 16 (42) | 15 (39) | 6 (16) | 1 (3) |
| Molecular profile EC N (%) | ||||||||
| MMRd | 14 (52) | 9 (33) | 4(15) | 0 (0) | 13 (48) | 9 (33) | 4 (15) | 1 (4) |
| p53 abnormal | 16 (47) | 11 (32) | 6(18) | 1 (3) | 17 (50) | 8 (24) | 8 (24) | 1 (2) |
| NSMP | 11 (58) | 7 (37) | 0 (0) | 1 (5) | 11 (50) | 8 (24) | 0 (0) | 1 (6) |
| Histology CC N (%) | ||||||||
| Squamous | 12 (71) | 3 (18) | 2(12) | 0 (0) | 10 (55) | 5 (29) | 2 (15) | 0 (0) |
| adenocarcinoma | 6 (60) | 1 (10) | 1(10) | 2 (20) | 4 (40) | 2 (20) | 2 (20) | 2 (20) |
| CPS CC N (%) | ||||||||
CPSConclusionsHER2-OE was relatively low across GTs, though certain histotypes and molecular features (HRD negative OCs, p53 abnormal EC and adenocarcinomas/CPS<1% CC) exhibited higher scores. The high CR suggests either scoring guideline may be suitable for GTs. HER2-OE's predictive/prognostic value in GTs requires further evaluation. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyVall d’Hebron Institute of Oncology. FundingHas not received any funding. DisclosureC. Garcia Duran: Financial Interests, Institutional, Invited Speaker: MSD-AstraZeneca, GSK; Financial Interests, Institutional, Other, Educative activity: EISAI; Financial Interests, Personal, Other, Travel expenses: GSK, AstraZeneca. J.F. Grau Béjar: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK; Financial Interests, Personal, Other, Educational Activities: AstraZeneca; Financial Interests, Personal, Other, Travel Expenses: GSK. D.G. Illescas: Financial Interests, Personal, Other, Travel expenses: GSK, MSD-AstraZeneca; Financial Interests, Personal, Invited Speaker: GSK. L. Fariñas Madrid: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Institutional, Invited Speaker: AstraZeneca & MSD, Pharma&; Financial Interests, Personal, Invited Speaker: Eisai, GSK. G. Villacampa: Financial Interests, Personal, Invited Speaker, Invited speaker in a course: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Invited speaker in an internal training: Pierre Fabre, GSK; Financial Interests, Personal, Invited Speaker, Internal discussion about the interpretation of some published results: Pfizer; Financial Interests, Personal, Other, Collaborations with specific projects: Reveal Genomics. A. Oaknin: Financial Interests, Personal, Advisory Board: Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, F. Hoffmann-La Roche, GSK, Genmab, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Novocure, OncoXerna Therapeutics, Inc, PharmaMar, Regeneron, Shattuck Labs, Seagen/Pfizer, Sutro Biopharma, Exelisis, Daiichi Sankyo, Debiopharm International, Myriad Genetics, Zentalis; Financial Interests, Personal, Other, Travel and accommodation: AstraZeneca, PharmaMar, Roche; Financial Interests, Institutional, Funding: Amgen, AbbVie Deutschland, Advaxis Inc., Aeterna Zentaris, Aprea Therapeutics AB, Regeneron Pharmaceuticals, Clovis Oncology Inc, Eisai limited LTD, F. Hoffmann –La Roche LTD, ImmunoGen Inc, Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc, PharmaMar SA, Tesaro Inc., Bristol Myers Squibb; Non-Financial Interests, Leadership Role, on behalf of GEICO: GCIG; Non-Financial Interests, Officer, Chair of Gynaecological Track ESMO 2019. Scientific Track Member Gynaecological Cancers ESMO 2018, ESMO 2020, ESMO 2022. Member of Gynaecological Cancers Faculty and Subject Editor Gyn ESMO Guidelines: ESMO; Non-Financial Interests, Leadership Role, ESMO GYN Co-Chair 2023 - 2025: ESMO; Non-Financial Interests, Leadership Role, Chair de Cervix Committee. 2022-2024: GCIG; Non-Financial Interests, Member: ESMO, ASCO, GCIG, SEOM, GOG. All other authors have declared no conflicts of interest. Resources from the same session751P - Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trialPresenter: Carol Aghajanian Session: Poster session 02 752P - Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survivalPresenter: Tibor Zwimpfer Session: Poster session 02 753P - Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trialPresenter: Felix Blanc-Durand Session: Poster session 02 754P - Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)Presenter: Ronnie Shapira-Frommer Session: Poster session 02 755P - Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancerPresenter: Maj Kamille Kjeldsen Session: Poster session 02 756P - Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancerPresenter: Junsik Park Session: Poster session 02 757P - Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R studyPresenter: Juan Cueva Banuelos Session: Poster session 02 758P - Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patientsPresenter: Emese Zsiros Session: Poster session 02 759P - JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studiesPresenter: Qunxian Rao Session: Poster session 02 760P - Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trialPresenter: Jie Tang Session: Poster session 02 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| ||||||||